Is ABT stock a Buy, Sell, or Hold?

Based on our analysis, ABT is currently a WAIT with low confidence. 📊 MIXED SIGNALS: ABT shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of ABT stock?

Our analysis estimates the fair value range for ABT to be between $106.15 and $113.71. The current price is $101.95.

What is the analyst price target for ABT?

The average Wall Street analyst price target for ABT is $120.21. This implies a potential upside of 17.9% from current levels.

Abbott Laboratories (ABT) Stock: Buy, Sell, or Hold?

ABT - Abbott Laboratories

PHARMACEUTICAL PREPARATIONS

$101.95

-1.41 (-1.36%) ▼

5d: -6.29%

30d: -8.08%

90d: +13.72%

WAIT

LOW Confidence

Protect Your ABT Gains

Analysis Updated: Sep 11, 2026 12:00 AM ET

Earnings: Oct 21, 2026

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Sep 4, 2026 at $108.33 · last confirmed Sep 9, 2026

Strength: 9.0/10

Get Alerted When ABT Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: ABT shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 9.9%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$148.37

Based on 7.0% avg growth

INTRINSIC VALUE TODAY

$92.13

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.5x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: ABT is currently trading at $101.95, which is considered oversold relative to its 30-day fair value range of $106.15 to $113.71. The stock's valuation (Forward PE: 16.8) is in line with its historical norms (17.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, ABT is in a strong uptrend. The price is currently testing key support at $101.49. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: ABT scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $120.21 (+17.9%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $106.15 - $113.71

Company Quality Score 41/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 54.8%

Protect Your Profits

Holding ABT? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
BEARISH: Weak technical setup (24/100)
BULLISH: High volume confirmation
BULLISH: Trading below Wall St target ($120.21)
WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $106.15 - $113.71

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $101.49

Resistance Level $113.91

Current Trend Strong Uptrend

Technical data as of Sep 11, 2026

Fundamental Context

Forward P/E (Next Year Est.) 16.81

Wall Street Target $120.21 (+17.9%)

Revenue Growth (YoY) 13.0%

Earnings Growth (YoY) -47.5%

Profit Margin 11.7%

Valuation Discount vs History -1.4% cheaper

PE vs Historical 16.8 vs 17.5 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -1.4% (market-implied from PE analysis)

1-Year Target $100.52 (-1%)

2-Year Target $99.12 (-3%)

3-Year Target $97.73 (-4%)

3-Yr Target (if PE normalizes) (PE: 17→18) $101.74 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.2, Growth: 9.9%) $162.35 (+59%)

Base: (SPY PE: 16.8, Growth: 9.9%) $135.30 (+33%)

Bear: (PE: 14.3, Growth: 9.9%) $115.01 (+13%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (17x PE) as earnings recover.

Trailing PE: 34.00 | Current EPS (TTM): $3.04

Bull Case $226.83 (+123%)

Analyst growth 99.5%, PE expands to 37.4

Base Case $206.21 (+102%)

Market implied 99.5%, PE stable at 34.0

Bear Case $70.28 (-31%)

Severe decline -20.0%, PE contracts to 28.9

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 16.8 to 17.5

Stabilization Target: $106.14 (+4.1%)

PE Expansion Potential: +4.1%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: September 12, 2026 8:16 PM ET
Data refreshes hourly during market hours. Next update: 9:16 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is ABT showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

Recent Transactions

Ro Khanna SELL 2026-03-30

Laura Friedman SELL 2026-03-24

Ro Khanna BUY 2026-03-23

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for ABT.

Create Free Account

Already have an account? Log In

Featured in Portfolios

ABT is a key holding in these high-performance investment strategies.

Dividend Aristocrats Income • +11.0% Return

View All Strategies

Top Rated Medical Devices Stocks

Top-rated stocks in Medical Devices by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
BSX Boston Scientific Corp	STRONG BUY 34 analysts	$63	49 HOLD
DXCM DexCom Inc	STRONG BUY 27 analysts	$94	40 HOLD
SYK Stryker Corporation	BUY 32 analysts	$383	44 HOLD
MDT Medtronic PLC	BUY 32 analysts	$105	52 HOLD
EW Edwards Lifesciences Corp	HOLD 32 analysts	$101	56 HOLD

BSX Boston Scientific…

49 HOLD

DXCM DexCom Inc

40 HOLD

SYK Stryker Corporati…

44 HOLD

MDT Medtronic PLC

52 HOLD

EW Edwards Lifescien…

56 HOLD

Advanced ABT Option Strategies

Professional options setups generated by AI based on today's ABT price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ABT

ABT Technical Chart ABT Price Prediction ABT Earnings Date ABT Investment Advisor ABT Fair Price Analyzer ABT Options Advisor ABT Options Chain ABT Options Analysis ABT Competitors

Compare ABT with Peers

ABT vs ABBV
Which one to buy?

ABT vs BMY
Which one to buy?

ABT vs JNJ
Which one to buy?

ABT vs MDT
Which one to buy?

ABT vs LLY
Which one to buy?

ABT vs PBH

BCTXW vs ABT

HRTX vs ABT
Winner: ABT

BGMS vs ABT

COCP vs ABT
Winner: ABT

CUE vs ABT
Winner: ABT

ABT vs QURE
Winner: ABT

ABT vs PTGX

CDTTW vs ABT

ABEO vs ABT
Winner: ABT

Create New Comparison View All Competitors

Tradestie